MyoKardia, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015
Net loss
Cash flow from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Depreciation and amortization
Depreciation
Amortization of discount on investments
Loss on disposal of equipment
Change in fair value of redeemable convertible preferred stock call option liability, net
Series A-1 Redeemable Convertible Preferred Stock
Total change in fair value of redeemable convertible preferred stock call option liability, net
Change in operating assets and liabilities:
Receivable from collaboration partner
Prepaid expenses and other current assets
Operating lease right-of-use assets
Other long-term assets
Accounts payable
Accrued liabilities
Prepayment from collaboration partner
Operating lease liabilities
Other long-term liabilities
Deferred revenue
Deferred revenue

Net cash used in operating activities
Cash flow from investing activities:
Purchases of investments
Sales of investments
Maturities of investments
Purchases of property and equipment
Proceeds from sale of equipment
(Increase) decrease in restricted cash
Proceeds from issuance of common stock during IPO, net of issuance costs
Net cash used in investing activities

Cash flow from financing activities:
Proceeds from issuance of common stock in follow-on offerings, net of issuance and financing costs
Follow-on Offering
Total proceeds from issuance of common stock in follow-on offerings, net of issuance and financing costs
Proceeds from issuance of common stock during IPO, net of issuance costs
Proceeds from issuance of Series B preferred stock, net of issuance costs
Proceeds from exercise of stock options
Proceeds from exercise of stock options and employee stock purchase plan
Payments of prior period offering costs
Net increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Net cash provided by financing activities

Net (decrease) increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period
Non-cash investing and financing activities:
Unpaid IPO-related costs included in period-end accrued liabilities
Unpaid financing-related costs included in period-end accounts payable
Unpaid financing-related costs included in period-end accrued liabilities
Vesting of early exercised options and restricted stock
Unpaid portion of property and equipment purchases included in period-end accounts payable and accrued liabilities
Unpaid portion of property and equipment purchases included in period-end accrued liabilities
Unpaid financing-related costs included in period-end accounts payable and accrued liabilities
Accretion of redeemable convertible preferred stock to redemption value
Accretion of dividends on redeemable convertible preferred stock

Comments